重组人脑利纳肽辅助治疗慢性心力衰竭疗效观察

目的观察重组人脑利纳肽(rhBNP)辅助治疗慢性心力衰竭(CHF)的临床疗效。方法选择60例慢性心力衰竭患者,随机分为治疗组和对照组,两组均给予常规治疗,治疗组在此基础上应用重组人脑利纳肽。观察两组患者治疗前后临床症状及左室射血分数(LVEF)、左室收缩末期内径(LVES)、左室舒张末期内径(LVEDD)和血浆脑钠肽(NTpro-BNP),并记录不良反应。结果治疗组的总有效率高于对照组(P<0.05);两组治疗后LVEF、LVEDD和NTpro-BNP比较差异有统计学意义(P<0.05);两组均无明显不良反应发生。结论在常规强心、利尿等治疗基础上加用重组人脑利纳肽辅助治疗慢性心力衰竭临床疗效确切,可明显改善CHF的心功能,用药安全性好。

Objectjve To observe the clinical effect of recombinant human brain natriuretic peptide on congestive heart failure patients. Mothods 60 patients admitted with congestive heart failure were randomly divided into two groups, treatment group with rhBNP and conventional treatment while control group with only conventional treatment. The condition of variation of the treatment fore and after and many correlative index including LVEF, LVES, LVEDD,NTpro-BNP and side effects were observed. Results The total effective rate of treatment group was significantly higher than control group（P〈 0.05）;The LVEF, LVES, LVEDD, NTpro-BNP of two groups after treatment were different with the index of two groups before treatment respectively（P〈0.05）;There were no significant side effects in two groups. Conclusion The treatment of rhBNP and conventional treatment with congestive heart failure patients is definite, rhBNP can significantly improve cardiac function,and has preferable security.